140 related articles for article (PubMed ID: 25913720)
1. Manipulation of B-cell responses with histone deacetylase inhibitors.
Waibel M; Christiansen AJ; Hibbs ML; Shortt J; Jones SA; Simpson I; Light A; O'Donnell K; Morand EF; Tarlinton DM; Johnstone RW; Hawkins ED
Nat Commun; 2015 Apr; 6():6838. PubMed ID: 25913720
[TBL] [Abstract][Full Text] [Related]
2. Effects of HDACi on Immunological Functions.
Winkler R; Kosan C
Methods Mol Biol; 2017; 1510():93-101. PubMed ID: 27761815
[TBL] [Abstract][Full Text] [Related]
3. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide.
Bishton MJ; Gardiner EE; Harrison SJ; Prince HM; Johnstone RW
Thromb Res; 2013 Jun; 131(6):514-20. PubMed ID: 23642854
[TBL] [Abstract][Full Text] [Related]
5. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
West AC; Mattarollo SR; Shortt J; Cluse LA; Christiansen AJ; Smyth MJ; Johnstone RW
Cancer Res; 2013 Dec; 73(24):7265-76. PubMed ID: 24158093
[TBL] [Abstract][Full Text] [Related]
6. HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2
Medon M; Vidacs E; Vervoort SJ; Li J; Jenkins MR; Ramsbottom KM; Trapani JA; Smyth MJ; Darcy PK; Atadja PW; Henderson MA; Johnstone RW; Haynes NM
Cancer Res; 2017 May; 77(10):2594-2606. PubMed ID: 28249907
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.
Lu HK; Gray LR; Wightman F; Ellenberg P; Khoury G; Cheng WJ; Mota TM; Wesselingh S; Gorry PR; Cameron PU; Churchill MJ; Lewin SR
PLoS One; 2014; 9(11):e113341. PubMed ID: 25409334
[TBL] [Abstract][Full Text] [Related]
10. Panobinostat for the management of multiple myeloma.
Sivaraj D; Green MM; Gasparetto C
Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419
[TBL] [Abstract][Full Text] [Related]
11. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
12. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
[TBL] [Abstract][Full Text] [Related]
13. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM
Front Immunol; 2019; 10():2512. PubMed ID: 31708928
[TBL] [Abstract][Full Text] [Related]
14. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice.
Wang D; Iclozan C; Liu C; Xia C; Anasetti C; Yu XZ
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1182-1190.e1. PubMed ID: 22698484
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.
Martin BP; Frew AJ; Bots M; Fox S; Long F; Takeda K; Yagita H; Atadja P; Smyth MJ; Johnstone RW
Int J Cancer; 2011 Jun; 128(11):2735-47. PubMed ID: 20715169
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Ge Z; Da Y; Xue Z; Zhang K; Zhuang H; Peng M; Li Y; Li W; Simard A; Hao J; Yao Z; Zhang R
Exp Neurol; 2013 Mar; 241():56-66. PubMed ID: 23261766
[TBL] [Abstract][Full Text] [Related]
17. Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors.
Sugimoto K; Itoh T; Takita M; Shimoda M; Chujo D; SoRelle JA; Naziruddin B; Levy MF; Shimada M; Matsumoto S
Transpl Int; 2014 Apr; 27(4):408-15. PubMed ID: 24410777
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Donor-Specific Antibody Production After Organ Transplantation by Valproic Acid: A Histone Deacetylase Inhibitor.
Ye J; Li J; Zhou M; Xia R; Liu R; Yu L
Transplantation; 2016 Nov; 100(11):2342-2351. PubMed ID: 27140514
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.
Jones RB; O'Connor R; Mueller S; Foley M; Szeto GL; Karel D; Lichterfeld M; Kovacs C; Ostrowski MA; Trocha A; Irvine DJ; Walker BD
PLoS Pathog; 2014 Aug; 10(8):e1004287. PubMed ID: 25122219
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors epigenetically promote reparative events in primary dental pulp cells.
Duncan HF; Smith AJ; Fleming GJ; Cooper PR
Exp Cell Res; 2013 Jun; 319(10):1534-43. PubMed ID: 23562654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
